Biotech company Geron Corporation (NASDAQ:GERN) has made a strong upward move this morning and gone up by 28% at the time of writing.
The rally in the stock might be linked to the announcement made by the company yesterday with regards to the publication of the data related to the IMbark Phase 2 trial in the Journal of Clinical Oncology. The paper in which the data has been published is titled “Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis.”
It is a major development for the company and the Geron stock had come into focus among investors yesterday as well. The continued rally in the stock this morning is an indication that the development has been welcomed by the market with great optimism. The publication highlighted key details like symptom response and overall survival rate among others. Investors could keep an eye on the price action in the Geron stock in the coming days.